- Portfolio Prep for Next Week: 'Don't Get Crazy'
- Strategists on Dubai: Avoid 'Rash Moves' Now
- Dubai Stock Market Fear Has 'Legs': Dennis Gartman
- Surprising Options Trades in TiVo Shares
- 10 Dividend Picks For Your Portfolio: Chief Investors
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Retail Earnings and Sales to Improve in Q4: Analyst
- 4 Food Stocks to Stuff in Your Portfolio: Analyst
- S&P at 1050-1200 Trading Range Next Year: Strategist
- U.S. Stocks Fall on Dubai Worries
- Black Friday at Best Buy
- Strategists on Dubai: Avoid 'Rash Moves' Now
- Longer Lines, Fuller Carts This Black Friday
- Dubai Stock Market Fear Has 'Legs': Dennis Gartman
- Obama's Emission Reduction Pledge Paints Future for Autos
- Is Super Bowl Halftime Act Too Old?
- Surprising Options Trades in TiVo Shares
- EA Sports Hopes to Pump Up Sales Through Pop-Up Locations
- UAE Markets Seen Limit Down on Monday Open
- Dubai's Debt Woes Signal New Era for Creditors
- US Treasury Wants Banks to Do More to Ease Mortgages
- Fed Audit Would Hurt Economic Prospects: Bernanke
- Next Week: Cash In Now Or Wait For A Santa Rally?
- Dubai Stock Selloff May Bring Buying Opportunity
- Black Friday Sales Rise by 0.5%: ShopperTrak
- Longer Lines, Fuller Carts This Black Friday
- Big US Banks May Be Forced to Raise Capital: Bove
RSS FEED
CNBC Stock Blog
Text Size 
Size doesn't necessarily matter when it comes to five-star investing. Just ask Frank Sustersic, portfolio manager for Turner Investment Partners.
His small-cap Turner Emerging Growth Fund is up an average of 16.40 percent per year over the last five years. It's currently closed to new investors, but Sustersic is willing to share some of his favorite names.
Recommendations:
Some of his favorite stocks are clinical-research organizations, or CROs.
"They help pharmaceutical companies conduct clinical-research trials," he told CNBC. "All of the companies right now have an amazing tailwind...and currently, there is a pretty significant outsourcing trend that's occurring; pharmaceutical and biotech companies are trying to change their cost structure to be more flexible."
Two of those CROs are Parexel
[PRXL
Loading...
()
] and Icon
[ICLR
Loading...
()
].
"Over the next three to six months, the stocks could need to consolidate a bit," he cautioned, but added, "Over the long-term period of time, I'm still optimistic about these stocks."
Sustersic also likes Ansys
[ANSS
Loading...
()
].
"Ansys makes (simulation) software used by engineers in product designs," he said. "They have a subscription model, so about 70 percent of their revenue base is recurring via subscription or licensing and maintenance."
(Contd.)
____________________________________
CNBC Stock Intelligence:
____________________________________
He's also enthusiastic about Willbros Group
[WG
Loading...
()
], a producer of large-diameter pipeline for natural-gas and oil companies.
"They recently got some big contract wins up in Canada," he noted. "They're probably sold out for the next year or so."
Rounding out his list -- and maybe, saving the best for last -- is Deckers Outdoor
[DECK
Loading...
()
], maker of the popular UGG brand boots.
"Very controversial, very volatile stock," he said, "It still looks like fantastic visibility going forward."
He said an informal survey of department-store buyers revealed that UGGs was the only apparel or shoe product that really sold well during the last holiday-shopping season.
"If anything, they regretted not ordering more," he said.
Disclosures:
Disclosure information for Frank Sustersic was not immediately available.
Data is a real-time snapshot *Data is delayed at least 15 minutes